tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Compugen (CGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACADResearch Report), Compugen (CGENResearch Report) and Deciphera Pharmaceuticals (DCPHResearch Report) with bullish sentiments.

ACADIA Pharmaceuticals (ACAD)

In a report issued on April 28, Jason Butler from JMP Securities maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $35.00. The company’s shares closed last Friday at $18.44.

According to TipRanks.com, Butler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.6% and a 35.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and Quoin Pharmaceuticals.

Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $29.23, which is a 54.8% upside from current levels. In a report issued on April 18, Leerink Partners also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Compugen (CGEN)

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Compugen on April 27 and set a price target of $9.00. The company’s shares closed last Friday at $2.38, close to its 52-week low of $2.27.

According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of -23.9% and a 22.8% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics.

Currently, the analyst consensus on Compugen is a Strong Buy with an average price target of $11.25, implying a 368.8% upside from current levels. In a report issued on April 12, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.

Deciphera Pharmaceuticals (DCPH)

In a report issued on April 28, Andrew Berens from Leerink Partners maintained a Buy rating on Deciphera Pharmaceuticals, with a price target of $15.00. The company’s shares closed last Friday at $10.12, close to its 52-week low of $6.51.

According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -11.8% and a 37.5% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

Deciphera Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $10.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed